Business Context and Reporting Period
Company: Icecure Medical Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2026 (Report dated May 19, 2026)
Context: The filing serves to incorporate a press release regarding clinical data presentation at the European Congress of Interventional Oncology (ECIO) 2026 and the status of a breast cryoablation MasterClass.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 6-K is a current report focused on corporate news and clinical updates rather than financial performance.
Material Changes
No material financial changes versus the prior comparable period are disclosed in this filing. The primary material update is the announcement of clinical efficacy data for the Company's ProSense® system.
Guidance, Outlook, and Management Commentary
- Clinical Data: ProSense® reported a nearly 90% recurrence-free rate for cryoablation of kidney cancer, data presented at ECIO 2026.
- Market Activity: The Company's first-ever Breast Cryoablation MasterClass was reported as overbooked.
- Regulatory Status: The report (excluding specific paragraphs of the press release) is incorporated by reference into the Company's Registration Statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for specific details on the study design and patient population behind the 90% recurrence-free rate.
- Confirm the commercial implications of the "overbooked" MasterClass for future revenue projections.
- Review the Company's most recent Form 20-F or quarterly report for actual financial metrics, as this filing contains none.
- Check for any regulatory approvals or pending decisions related to the kidney cancer and breast cryoablation indications mentioned.